Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Drops By 40.6%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 49,300 shares, a drop of 40.6% from the February 28th total of 83,000 shares. Based on an average daily volume of 2,640,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 6.6% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $350.00 price target on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

Windtree Therapeutics Trading Down 4.9 %

Windtree Therapeutics stock opened at $1.56 on Monday. The company has a market capitalization of $1.17 million, a P/E ratio of -0.09 and a beta of 0.68. Windtree Therapeutics has a 1-year low of $1.45 and a 1-year high of $737.44. The firm’s fifty day simple moving average is $4.74 and its 200-day simple moving average is $31.46.

Institutional Investors Weigh In On Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new position in Windtree Therapeutics, Inc. (NASDAQ:WINT) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned 1.08% of Windtree Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 29.33% of the company’s stock.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.